Outlook Therapeutics Prices $55M Offering at $0.99, Deep Discount to Market
OTLK has more than doubled off its 52-week low of $0.161 on light trading volume (0.4× avg).
Summary
Outlook Therapeutics priced a $55M public offering of 55.6M shares plus warrants at $0.99 per unit, a 6% discount to the $0.93 market price. The warrants carry a $1.10 strike, are immediately exercisable, and expire in five years. The share count alone increases by roughly 27% before any warrant exercise or the underwriters' 8.3M-share option. The company expects aggregate gross proceeds of approximately $55M from the offering, which will help support the commercial launch of LYTENAVA in the U.S. following its July FDA approval. The offering is expected to close August 14, 2026.
At the time of this announcement, OTLK was trading at $0.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $205.7M. The 52-week trading range was $0.16 to $3.39. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.